RxDoctor Payments Data

Joshua Belle

Surgery · Omaha, NENPI 1043692494

Payments from drug & device makers

$2,144in general payments, 2019–2025

Across 28 payments — averaging $76.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Boston Scientific$200
  • Conmed Corporation$193
  • Intuitive Surgical$123
  • Astellas Pharma US Inc$100
  • Coloplast$93
  • plus $403 from 10 others

What the payments were for

  • Travel & lodging$85240%
  • Food & beverage$1,19356%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,144 in reported general payments places this provider in the 60th percentile of 197 surgery providers in Nebraska.

See all surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$62,077
Medicare patients
263
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron94$74,249
PremarinEstrogens, Conjugated15$6,621
Tamsulosin Hcl303$5,377
Finasteride158$3,086
Oxybutynin Chloride ErOxybutynin Chloride62$1,861
Potassium Citrate ErPotassium Citrate17$1,654
Tolterodine Tartrate ErTolterodine Tartrate26$992
Terazosin Hcl12$458
Tadalafil12$291
Betamethasone Valerate11$233
Meloxicam43$180
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$175
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$162
Oxycodone Hcl13$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$74,24994 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 197 surgery providers in Nebraska.

Other surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →